Rhenman & Partners Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.7M | Sell |
207,000
-8,000
| -4% | -$466K | 1.44% | 24 |
|
|
2025
Q4 | $12.8M | Buy |
215,000
+28,350
| +15% | +$1.54M | 1.19% | 32 |
|
|
2025
Q3 | $10.1M | Buy |
186,650
+37,000
| +25% | +$2.12M | 1.12% | 35 |
|
|
2025
Q2 | $8.23M | Sell |
149,650
-115,350
| -44% | -$6.79M | 1.04% | 37 |
|
|
2025
Q1 | $18.7M | Buy |
265,000
+14,377
| +6% | +$967K | 2.15% | 19 |
|
|
2024
Q4 | $16.5M | Sell |
250,623
-113,877
| -31% | -$7.63M | 1.69% | 22 |
|
|
2024
Q3 | $25.6M | Buy |
364,500
+113,000
| +45% | +$9.45M | 2.08% | 19 |
|
|
2024
Q2 | $20.7M | Buy |
251,500
+14,000
| +6% | +$1.17M | 1.99% | 18 |
|
|
2024
Q1 | $20.7M | Sell |
237,500
-45,000
| -16% | -$4.03M | 1.97% | 20 |
|
|
2023
Q4 | $27.2M | Sell |
282,500
-97,500
| -26% | -$8.63M | 2.72% | 8 |
|
|
2023
Q3 | $33.6M | Hold |
380,000
| – | – | 3.63% | 3 |
|
|
2023
Q2 | $32.9M | Buy |
380,000
+155,000
| +69% | +$14.6M | 3.47% | 2 |
|
|
2023
Q1 | $21.4M | Sell |
225,000
-29,000
| -11% | -$3.01M | 2.35% | 18 |
|
|
2022
Q4 | $26.3M | Buy |
254,000
+17,000
| +7% | +$1.6M | 2.74% | 6 |
|
|
2022
Q3 | $20.5M | Buy |
237,000
+97,000
| +69% | +$8.64M | 2.15% | 17 |
|
|
2022
Q2 | $11.6M | Sell |
140,000
-80,000
| -36% | -$6.37M | 1.32% | 30 |
|
|
2022
Q1 | $17M | Sell |
220,000
-45,000
| -17% | -$3.77M | 1.67% | 23 |
|
|
2021
Q4 | $23.6M | Buy |
265,000
+25,000
| +10% | +$2.06M | 1.57% | 20 |
|
|
2021
Q3 | $18.6M | Buy |
240,000
+80,000
| +50% | +$6.31M | 1.3% | 33 |
|
|
2021
Q2 | $13.3M | Sell |
160,000
-20,000
| -11% | -$1.59M | 0.91% | 46 |
|
|
2021
Q1 | $13.6M | Sell |
180,000
-330,000
| -65% | -$27M | 0.95% | 43 |
|
|
2020
Q4 | $44.7M | Sell |
510,000
-234,354
| -31% | -$18.6M | 3.65% | 2 |
|
|
2020
Q3 | $56.6M | Buy |
744,354
+554,354
| +292% | +$56.1M | 5.04% | 1 |
|
|
2020
Q2 | $23.4M | Buy |
190,000
+5,155
| +3% | +$512K | 2.53% | 5 |
|
|
2020
Q1 | $15.6M | Sell |
184,845
-25,155
| -12% | -$2.17M | 2.19% | 11 |
|
|
2019
Q4 | $17.8M | Sell |
210,000
-80,491
| -28% | -$6.08M | 1.95% | 13 |
|
|
2019
Q3 | $19.6M | Buy |
290,491
+9,142
| +3% | +$704K | 2.45% | 10 |
|
|
2019
Q2 | $24.1M | Buy |
281,349
+49,800
| +22% | +$4.26M | 2.65% | 10 |
|
|
2019
Q1 | $20.6M | Buy |
231,549
+55,000
| +31% | +$5.1M | 2.41% | 12 |
|
|
2018
Q4 | $15M | Sell |
176,549
-88,300
| -33% | -$8.4M | 1.72% | 22 |
|
|
2018
Q3 | $25.7M | Buy |
264,849
+25,000
| +10% | +$2.5M | 2.57% | 6 |
|
|
2018
Q2 | $22.6M | Buy |
239,849
+35,000
| +17% | +$3.07M | 2.31% | 12 |
|
|
2018
Q1 | $16.6M | Buy |
204,849
+65,000
| +46% | +$5.58M | 2.05% | 19 |
|
|
2017
Q4 | $12.5M | Sell |
139,849
-40,100
| -22% | -$3.49M | 1.69% | 23 |
|
|
2017
Q3 | $16.7M | Sell |
179,949
-9,351
| -5% | -$826K | 2.14% | 12 |
|
|
2017
Q2 | $17.2M | Buy |
189,300
+64,300
| +51% | +$5.85M | 2.47% | 8 |
|
|
2017
Q1 | $11M | Buy |
125,000
+75,000
| +150% | +$6.67M | 1.74% | 20 |
|
|
2016
Q4 | $4.14M | Sell |
50,000
-90,000
| -64% | -$7.74M | 0.79% | 50 |
|
|
2016
Q3 | $13M | Sell |
140,000
-10,000
| -7% | -$942K | 2.06% | 13 |
|
|
2016
Q2 | $11.7M | Sell |
150,000
-40,000
| -21% | -$3.4M | 2.07% | 12 |
|
|
2016
Q1 | $15.7M | Buy |
190,000
+72,000
| +61% | +$5.86M | 3.11% | 3 |
|
|
2015
Q4 | $12.4M | Buy |
118,000
+32,000
| +37% | +$3.34M | 1.87% | 16 |
|
|
2015
Q3 | $9.06M | Sell |
86,000
-6,000
| -7% | -$801K | 1.44% | 28 |
|
|
2015
Q2 | $12.6M | Buy |
92,000
+17,000
| +23% | +$2.11M | 1.51% | 18 |
|
|
2015
Q1 | $9.35M | Buy |
75,000
+14,000
| +23% | +$1.48M | 1.58% | 22 |
|
|
2014
Q4 | $5.51M | Sell |
61,000
-31,000
| -34% | -$2.58M | 1.6% | 20 |
|
|
2014
Q3 | $6.64M | Sell |
92,000
-58,000
| -39% | -$3.81M | 1.94% | 10 |
|
|
2014
Q2 | $9.33M | Buy |
150,000
+4,736
| +3% | +$286K | 2.77% | 7 |
|
|
2014
Q1 | $9.91M | Buy |
145,264
+45,264
| +45% | +$3.34M | 2.97% | 6 |
|
|
2013
Q4 | $7.03M | Buy |
+100,000
| New | +$6.79M | 2.75% | 7 |
|
Other funds holding BMRN
VCM
VPM
Rhenman & Partners Asset Management's BMRN Position: Q1 2026 in Review
Rhenman & Partners Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 3.7% in Q1 2026, selling an estimated $466K and leaving 207,000 shares worth $11.7M. The position accounts for 1.44% of the portfolio, ranked #24.
Rhenman & Partners Asset Management first reported a position in BMRN in Q4 2013 and has held it in 50 quarters since. The position peaked at $56.6M in Q3 2020. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Rhenman & Partners Asset Management held 207,000 shares of BioMarin Pharmaceuticals worth $11.7M as of Q1 2026.
- Rhenman & Partners Asset Management sold 8,000 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $466K.
- BioMarin Pharmaceuticals made up 1.44% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #24 holding.
- Rhenman & Partners Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
- Rhenman & Partners Asset Management's BioMarin Pharmaceuticals position peaked at $56.6M in Q3 2020.
- 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.